Intellipharmaceutics International Inc. Quarterly Interest Expense in USD from Q1 2013 to Q3 2023

Taxonomy & unit
us-gaap: CAD and USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Intellipharmaceutics International Inc. quarterly/annual Interest Expense history and growth rate from Q1 2013 to Q3 2023.
  • Intellipharmaceutics International Inc. Interest Expense for the quarter ending August 31, 2023 was $66.9K, a 26.1% increase year-over-year.
  • Intellipharmaceutics International Inc. Interest Expense for the twelve months ending August 31, 2023 was $234K, a 42.7% decline year-over-year.
  • Intellipharmaceutics International Inc. annual Interest Expense for 2022 was $292K, a 46.9% decline from 2021.
  • Intellipharmaceutics International Inc. annual Interest Expense for 2021 was $549K, a 43.4% decline from 2020.
  • Intellipharmaceutics International Inc. annual Interest Expense for 2020 was $970K, a 292% increase from 2019.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $234K $66.9K +$13.9K +26.1% Jun 1, 2023 Aug 31, 2023 6-K 2023-10-16
Q2 2023 $220K $51.9K -$21.6K -29.4% Mar 1, 2023 May 31, 2023 6-K 2023-09-26
Q1 2023 $242K $50.8K -$49.8K -49.5% Dec 1, 2022 Feb 28, 2023 6-K 2023-09-26
Q4 2022 $292K $64.6K -$117K -64.5% Sep 1, 2022 Nov 30, 2022 20-F/A 2024-02-06
Q3 2022 $409K $53K -$159K -75% Jun 1, 2022 Aug 31, 2022 6-K 2023-10-16
Q2 2022 $568K $73.5K -$5.97K -7.52% Mar 1, 2022 May 31, 2022 6-K 2023-09-26
Q1 2022 $574K $101K +$25K +33% Dec 1, 2021 Feb 28, 2022 6-K 2023-09-26
Q4 2021 $549K $182K +$99.5K +121% Sep 1, 2021 Nov 30, 2021 20-F/A 2024-02-06
Q3 2021 $450K $212K +$79.3K +59.6% Jun 1, 2021 Aug 31, 2021 6-K 2022-10-14
Q2 2021 $370K $79.4K -$101K -55.9% Mar 1, 2021 May 31, 2021 6-K 2022-07-21
Q1 2021 $471K $75.6K -$498K -86.8% Dec 1, 2020 Feb 28, 2021 6-K 2022-04-14
Q4 2020 $970K $82.3K +$4.62K +5.95% Sep 1, 2020 Nov 30, 2020 20-F/A 2024-02-06
Q3 2020 $965K $133K +$77.4K +139% Jun 1, 2020 Aug 31, 2020 6-K 2021-10-15
Q2 2020 $888K $180K +$125K +226% Mar 1, 2020 May 31, 2020 6-K 2021-07-15
Q1 2020 $763K $574K +$515K +876% Dec 1, 2019 Feb 29, 2020 6-K 2021-04-14
Q4 2019 $248K $77.7K +$1.86K +2.45% Sep 1, 2019 Nov 30, 2019 20-F/A 2022-05-09
Q3 2019 $246K $55.7K -$4.17K -6.96% Jun 1, 2019 Aug 31, 2019 6-K 2020-10-15
Q2 2019 $250K $55.3K -$5.86K -9.59% Mar 1, 2019 May 31, 2019 6-K 2020-07-15
Q1 2019 $256K $58.8K +$457 +0.78% Dec 1, 2018 Feb 28, 2019 6-K 2020-05-29
Q4 2018 $255K $75.8K Sep 1, 2018 Nov 30, 2018 20-F 2021-03-31
Q3 2018 $59.9K -$31.5K -34.5% Jun 1, 2018 Aug 31, 2018 6-K 2019-10-11
Q2 2018 $61.2K -$42.2K -40.8% Mar 1, 2018 May 31, 2018 6-K 2019-07-10
Q1 2018 $58.4K Dec 1, 2017 Feb 28, 2018 6-K 2019-04-15
Q3 2017 $91.4K Jun 1, 2017 Aug 31, 2017 6-K 2018-10-15
Q2 2017 $103K Mar 1, 2017 May 31, 2017 6-K/A 2018-07-24
Q1 2014 $82.3K +$16.9K +25.8% Dec 1, 2013 Feb 28, 2014 6-K 2014-04-14
Q1 2013 $65.4K Dec 1, 2012 Feb 28, 2013 6-K 2014-04-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.